A novel insight into the pathophysiology of autoimmune hepatitis: An immune activator mutation in the FLT3 receptor

Muhammed Yuksel1,2, Ayse Armutlu3, Farinaz Nazmi1,2, Serdar Ceylaner4, Cigdem Arikan1,2

1Paediatric Gastroenterology-Hepatology/Liver Transplantation Centre, Koç University, Istanbul, Turkey; 2Research Centre for Translational Medicine (KUTTAM)-Liver Immunology Laboratory, Koç University, Istanbul, Turkey; 3Department of Pathology, Koç University Hospital, Istanbul, Turkey; 4Intergen Diagnostic Centre for Genetic Disorders, Ankara, Turkey

Abstract
Autoimmune hepatitis (AIH) is a chronic progressive autoimmune liver disease characterized by hypergammaglobulinemia, interface hepatitis, a female preponderance, and the presence of autoantibodies in most patients. The presence of HLA-DR3/DR4 and functional impairment in regulatory T cells are associated with AIH. However, AIH is a multifactorial complex disease. This report is a description of a case of seronegative AIH in a girl with chronic hepatitis, a high immunoglobulin E (IgE) level, perforating nodular dermatitis, and eosinophilia. Re-evaluate the diagnosis, whole exon sequencing was performed. It was determined that the patient had ancestral haplotype A1-B8-DR3, which is associated with autoimmunity. Importantly, it was also noted that an undocuidgeted point mutation (Ala627Thr) of the FMS-like tyrosine 3 kinase (FLT3) receptor was present. This FLT3 receptor gain-of-function mutation is associated with the activation of the mechanistic target of rapamycin (mTOR), and dendritic cell activation. In addition, a loss-of-function mutation in the melanocortin-3 receptor gene, which inhibits interleukin 4, was detected. The constellation of these immune deregulatory factors may have propagated auto-aggression of the liver, causing chronic hepatitis with AIH features. The findings of seronegativity with eosinophilia and a high IgE level led us to hypothesize that the pathognomonic mechanism in this case was unlike that of classic AIH pathophysiology. Since mTOR is constitutively activated, mTOR inhibitors may be a useful option to treat AIH and dermatitis.

Keywords: Autoimmune hepatitis; liver disease; mutation.

Introduction
Autoimmune hepatitis (AIH) is a chronic, progressive, autoimmune liver disease, characterized by lymphocyticplasmic infiltrate the portal areas leading to fibrosis, and eventually cirrhosis in 38% of cases.1 Autoantibodies, such as anti-smooth muscle actin, anti-nuclear antibody, anti-liver–kidney microsomal type 1, and anti-liver cytosol type 1, are present in more than 80% of AIH patients, in addition to hypergammaglobulinemia.3 However, as many as 10% of AIH patients are seronegative for these autoantibodies. The complete etiology of AIH remains poorly understood. It has been established that human leucocyte antigen (HLA) class II alleles, such as HLA-DR3/DR4/DR7 and the ancestral haplotype A1-B8-DR3, are associated with AIH. Variations in non-HLA alleles, such as CLTA4, GATA2, and TNFA, have also been associated with AIH. However, genetic studies investigating the incidence of AIH in first-degree relatives and concordance in monozygotic twins demonstrated that AIH is a multifactorial complex disease that requires further research.

Case Report
This is a case of AIH in a 12-year-old girl. She presented with signs of liver injury but without jaundice, including an elevated alanine aminotransferase level (ALT >2000 IU/L), autoantibody seronegativity, and vast peripheral eosinophilia both proportionally (>20%, normal range: 0.7–5.8%) and in terms of count (1.82x109/uL, normal range: 0.04–0.38x109/uL), in addition to an elevated monocyte count (Fig. 1a–c). Furthermore, the patient had conspicuous skin lesions, diagnosed as nodular perforating dermatitis (Appendix Fig. 1a, b). Liver histology demonstrated typical features of AIH with portal inflammation composed of multi-focal interface hepatitis with cluster of differentiation 3 (CD3+T) lymphocyte, CD20+B cell, and CD38+plasma cell infiltration; a rosette formation (Fig. 2a–f); no biliary changes; and mild fibrosis (Ishak score grade 2). An AIH score of 7 was recorded according to the 2018 scoring system to diagnose pediatric autoimmune liver diseases,4 and defined as probable AIH (Appendix Table 1). Apart from dermatitis, no other co-morbidities were detected, including infectious pathogens (Appendix Table 2). Magnetic resonance cholangiography results were normal. Both the bone marrow aspirate and the endoscopy findings were unremarkable, and did not support an aberrant eosinophilic infiltration, which excluded hypereosinophilic syndrome. Standard immunosuppressive therapy (steroids/azathioprine) was initiated according to AIH guidelines1 Specifically, the initial treatment consisted of 60 mg/day steroids, tapered in the following 4 weeks to 5 mg/day, but subsequently increased to 10 mg/day. Azathioprine (50 mg/ day) was initiated and increased to 100 mg/day. The patient responded to the treatment; there was an alamine aminotransferase decrease of >90% to 100–200 IU/L within 4 weeks (Fig. 1a). Low-grade fluctuating hepatitis, high IgE, the reappearance of sheer eosinophilia, (Fig. 1b) and high blood monocyte counts at diagnosis and thereafter (Appendix
Table 3) prompted us to re-evaluate the initial diagnosis based on a suspicion of an immune dysregulation. Whole exon sequencing (WES) was performed and the results demonstrated that the patient had the ancestral haplotype A1-B8-DR3 (associated with AIH), a loss-of-func-
Case Report

Discussion
The classic presentation of AIH does not include a high IgE count, shear eosinophilia, perforating nodular dermatitis, or borderline monocytosis. In this case, the atypical presentation led us to conduct a comprehensive investigation. WES revealed different (novel) pathological mutations that potentially explained the findings. To the best of our knowledge, this is the first known instance of a gain-of-function mutation in the FLT3 receptor oncogene in a child with AIH. FLT3 has critical roles in regulating immune homeostasis. It is a transmembrane-bound receptor tyrosine kinase and is activated by the FLT3 ligand (FLT3L) (Fig. 2g). FLT3L binding leads to dimerization of the FLT3 receptor and activation of downstream kinase-signaling pathways, including the mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription (STAT), and mammalian target of rapamycin (mTOR) pathways. This mutation likely causes excess phosphorylation-mediated over-activation of the receptor, conceivably leading to uncontrolled innate and adaptive immune activation. Gain-of-function mutations of the FLT3 receptor have been reported to have expanded dendritic cells (DCs), which stimulated the proliferation of T cells and regulatory T cells (Tregs). Our patient had the A1-B8-DR3 haplotype. HLA-DR3/HLA-DR4, as well as A1-B8-DR3, has been linked with Tregs functional impairment in mice and humans. This combination could cause a loss of tolerance in T cells and, potentially facilitating autoimmunity in the liver and leading to AIH.

In addition, our patient had dermatitis, which could also be linked to over-activated FLT3 receptor-mediated DC accumulation. Yan et al. reported that in mice, use of an FLT3 inhibitor decreased the number and activation of DCs and led to improvement in skin lesions. In addition to FLT3-related immune dysregulation, the loss-of-function mutation of the MC3R gene could also explain dermatitis, a high IgE count, and eosinophilia. This mutation has often been linked to obesity in humans, but it has also been shown that the interaction between MC3R and its ligand, α-melanocyte-stimulating hormone (α-MSH), suppressed atopic dermatitis in a mouse model. Also, α-MSH reduced the eosinophil count and the serum level of IgE, IL-4, and IL-5 in asthmatic mice. We concluded that MC3R activity appeared to have an anti-TH2 effect and a mutation of this gene may have caused the atopic dermatitis seen in our patient.

In conclusion, it is likely that this patient requires close monitoring, as she is at increased risk of developing leukemia. Most importantly, it is noteworthy that seronegative AIH co-occurring with a high IgE count and eosinophilia led us to wonder if the pathognomonic mechanisms involved in this case led to a presentation unlike the classical AIH pathophysiology. mTOR inhibitors may be a useful drug option to treat autoimmunity, dermatitis, and eosinophilia. Genetic alterations that lead to immune dysregulation should be a consideration in children with seronegative AIH and eosinophilia.

References
1. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases. Hepatology 2020;72(2):671-722.
2. Nouri-Aria KT, Donaldson PT, Hegarty JE, Eddieston AL, Williams R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol 1985;1(3):235-241.
3. Lammert C. Genetic and Environmental Risk Factors for Autoimmune Hepatitis. Clin Liver Dis (Hoboken) 2019;14(1):9-32.
4. Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and management of pediatric autoimmune liver disease: esphgan hepatology committee position statement. J Pediatr Gastroenterol Nutr 2018;66(2):345-360.
5. Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci 2018;19(10):3198.
6. Lau CM, Nish SA, Yogeov N, Waisman A, Reiner SL, Reizis B. Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med 2016;213(3):415-431.
7. Yuksel M, Wang Y, Tai N, Peng J, Guo J, Beland K, et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015;62(5):1536-1550.
8. Yuksel M, Xiao X, Tai N, Vijay M, Gilden E, Beland K, et al. The induction of autoimmune hepatitis in the human leukocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model. Clin Exp Immunol 2016;186(2):164-176.
9. Yan HX, Li WW, Zhang Y, Wei XW, Fu LX, Shen GB, et al. Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor. Immunol Res 2014;60(1):112-126.
### Appendix Table 1. Juvenile autoimmune liver disease diagnostic scoring system

| Parameter                        | Feature     | Score for AIH | Case |
|----------------------------------|-------------|---------------|------|
| ANA and/or SMA                   | ≥1:20       | +1            | 0    |
|                                  | ≥1:80       | +2            |      |
| Anti-LKM1 titres                 | ≥1:10       | +1            | 0    |
|                                  | ≥1:80       | +2            |      |
| Anti-LC1                         | Positive    | +2            | 0    |
| Anti-SLA                         | Positive    | +2            | 0    |
| pANNA                            | Positive    | +2            | 0    |
| Serum IgG (x ULN)                | >ULN        | +1            |      |
|                                  | >1:20 ULN   | +2            | +1   |
| Liver histology                  | Compatible with AIH | +1 |      |
|                                  | Typical of AIH | +2 | +2   |
| Absence of viral hepatitis (A, B, E, EBV), NASH, Wilson’s disease, and drug exposure | Yes | +2 | +2   |
| Presence of extrahepatic autoimmunity | Yes | +1 | 0    |
| Family history of autoimmunity   | Yes         | +1            | 0    |
| Cholangiography                  | Normal      | +2            | +2   |
|                                  | Abnormal    | -2            |      |
| Total                            | +7          |               |      |
| Total score                      |             |               |      |
| ≥7: Probable AIH                 |             |               |      |
| >8: Definite AIH                 |             |               |      |

* The European Society for Paediatric Gastroenterology Hepatology and Nutrition, 2018. AIH: Autoimmune hepatitis; ANA: Anti-nuclear-antibody; Anti-LC1: Anti-liver cytosol; Anti-LKM1: Anti-liver–kidney microsomal type-1; Anti-SLA: Anti-soluble liver antigen; EBV: Epstein-Barr virus; NASH: Non-alcoholic steatohepatitis; pANNA: Peripheral anti-nuclear neutrophil antibody; SMA: Smooth-muscle antibody; ULN: Upper limit of normal.

### Appendix Table 2. Microbiology and virology

| Parameter                        | Value                | Reference value(s) |
|----------------------------------|----------------------|--------------------|
| Hepatitis C virus antibody       | 0.06 (Negative)      | <1                 |
| Hepatitis B virus surface antigen (HbsAg)| 0.19 (Negative)  | <1                 |
| Hepatitis B virus surface antibody| 24.49                | >10 mIU/mL for immunity |
| Anti-HIV                         | 0.04                 | <1                 |
| Coronavirus, SARS-CoV-2 RNA (PCR test) | Negative         | n/a                |
| Protozoan                        | Negative             | n/a                |
| Entamoeba histolytica            | Negative             | n/a                |
| Giardia lamblia                  | Negative             | n/a                |
| Cryptosporidium parvum           | Negative             | n/a                |
| Trichinella spiralis IgM         | Negative             | n/a                |
| Toxocara canis antibodies        | Negative             | n/a                |
| Ascaris IgG                      | 8.0                  | <10 (MONA)         |
| Fasciola hepatica antibodies     | <1:40 (Negative)     | <1:40              |
| Echinococcus granulosus          | <1:160 (Negative)    | <1:160             |
| Tuberculosis feron test          | Negative             | n/a                |

HIV: Human immunodeficiency virus; Ig: Immunoglobulin; MONA: Multiple of normal activity; n/a: not applicable; PCR: Polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
### Appendix Table 3. Leukocyte subtypes at diagnosis

| Parameter        | Present case | Range               |
|------------------|--------------|---------------------|
| CD3+ T cells     | 1757         | 800–3500 (cells/uL) |
| CD4+ T cells     | 1101         | 400–2100 (cells/uL) |
| CD8+ T cells     | 452          | 200–1200 (cells/uL) |
| CD14+ Monocytes  | 501          | 0–100 (cells/uL)    |
| CD20+ B cells    | 960          | 350–3200 (cells/uL) |
| CD56+ NK cells   | 320          | 25–1750 (cells/uL)  |

### Appendix Figure 1. Nodular perforating dermatitis. (a, b) Photos of the ulcerative skin lesions on the arm and forehead.